Dr. Neil Love

Breast Cancer Update

Science EN ↓ 123 episodes

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.

Be sure to visit the podcast's website and support the creator: www.researchtopractice.com

Author

Dr. Neil Love

Category

Science

Podcast website

www.researchtopractice.com

Latest episode

Nov 9, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates 29.09.2025

Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer.  CME information and select publications here .

Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management 23.09.2025

Prof Peter Schmid from Barts Cancer Institute in London reviews available efficacy and safety data guiding the optimal management of metastatic triple-negative breast cancer.  CME information and select publications here .

Metastatic Triple-Negative Breast Cancer — The Selection and Sequencing of Therapy 18.09.2025

Dr Ana C Garrido-Castro and Prof Peter Schmid review patient cases and provide insights regarding the treatment of metastatic triple-negative breast cancer.   CME information and select publications here .

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management 16.09.2025

Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management.    CME information and select publications here .

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management 15.09.2025

Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer the...

Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1 09.09.2025

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas review available efficacy and safety data guiding the optimal integration of oral SERDs into clinical practice.  CME information and select publications here .

Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates 01.09.2025

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm.   CME information and select publications here .

Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management Approaches 26.08.2025

Dr Sarah Sammons from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses cases and reviews the current management of brain metastases in patients with HER2-positive breast cancer.  CME information and select publications here .

Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates 04.08.2025

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator perspectives on the role of TROP2-directed antibody-drug conjugates in the management of HR-positive and triple-negative breast cancers.  CME information and select publications here .

Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management 29.07.2025

Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, discusses the efficacy and safety of approved and investigational antibody-drug conjugates for endocrine-resistant HR-positive and triple-negative metastatic breast cancer.  CME information and select publications here .

Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 04.07.2025

Dr Harold Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Joyce O’Shaughnessy and moderator Dr Hope S Rugo present data informing treatment decision-making for patients with metastatic breast cancer at the 2025 ASCO annual meeting.  CME information and select publications here .

IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies 23.06.2025

Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas.   CME information and select publications here .

For Oncology Nurses: Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS Congress 16.06.2025

Drs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported with clinical perspectives and management strategies from nurse practitioners Ms Jamie Carroll and Mr Ronald Stein.  NCPD information and select publications here .

Breast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and Advances 04.06.2025

Dr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with breast cancer.  CME information and select publications here .

5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer 28.05.2025

Dr Rinath Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.  CME information and select publications here .

5-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer 19.05.2025

Dr Rinath M Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.  CME information and select publications here .

Breast Cancer — Year in Review Series on Relevant New Datasets and Advances 06.05.2025

Dr Rebecca Dent from National Cancer Centre Singapore and Dr Nancy Lin from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss important efficacy and safety data from 2024 related to the management of localized and advanced breast cancers.  CME information and select publications here .

For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress 26.04.2025

Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events.  NCPD information and select publications here .

Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy 25.04.2025

Dr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast cancer and preexisting medical conditions.  CME information and select publications here .

HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit 21.04.2025

Clinical investigators discuss available data guiding the management of HER2-positive, triple-negative and localized breast cancer.   CME information and select publications here .

HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology Summit 13.04.2025

Clinical investigators discuss available data guiding the management of hormone receptor-positive metastatic breast cancer.  CME information and select publications here .

Breast Cancer — An Interview with Dr Adrienne G Waks on Recent Trial Updates 08.04.2025

Dr Adrienne G Waks from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews recent trial updates and their significance for the management of breast cancer.  CME information and select publications here .

Neurofibromatosis Type 1 Plexiform Neurofibromas — An interview with Dr Christopher L Moertel 28.03.2025

Dr Christopher L Moertel from the University of Minnesota in Minneapolis discusses the clinical presentation of and optimal management strategies for plexiform neurofibromas and malignancies associated with neurofibromatosis type 1.  CME information and select publications here .

HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based Therapy 28.03.2025

Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes data presented at the recent 2024 San Antonio Breast Cancer Symposium applicable to the management of HR-positive breast cancer.    CME information and select publications here .

5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer 22.03.2025

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.  CME information and select publications here .

Listen to the Breast Cancer Update podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.